Yesterday, Scholar Rock shared an SMA community update letter on their Biologics License Application (BLA) for apitegromab in SMA. As shared on September 23, 2025, Scholar Rock received a Complete Response Letter (CRL) from the FDA for the apitegromab BLA in SMA. As a reminder, the CRL was solely related to manufacturing observations identified at […]
Scholar Rock Releases SMA Community Update Letter on Apitegromab Read More »
Today, Biogen announced plans to initiate Phase 3 development to evaluate the effectiveness and safety of salanersen, an investigational drug for the treatment of spinal muscular atrophy (SMA). Phase 3 initiation follows the announcement of positive interim results of the Phase 1 study of salanersen, which informed the design of the studies. Biogen is preparing
Biogen to Initiate Phase 3 Pivotal Study Evaluating Investigational Drug Salanersen Read More »
Cure SMA has updated its Health Insurance Road Map to help patients, families, and providers navigate the complexities of health insurance. The updated resource reflects the current healthcare landscape and offers essential tools to simplify challenging insurance topics and promote informed decision-making. The Health Insurance Road Map includes: Clear definitions of commonly used insurance terms
Cure SMA Updates Health Insurance Road Map to Support Patients and Families Read More »
Cure SMA is excited to announce the launch of a brand-new equipment grant program, made possible through the generous support of the Luke 18:1 Foundation. This program will provide Fold & Go Travel Electric Wheelchairs to children and adults living with SMA that they will own outright, not borrow. Unlike our current equipment pool loan
Cure SMA and the Luke 18:1 Foundation Launch New Fold & Go Wheelchair Grant Program Read More »
